The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described. Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm800180e | DOI Listing |
Publication Analysis
Top Keywords
thrombin receptor
8
sch 530348
8
530348 potent
8
discovery novel
4
novel orally
4
orally active
4
active himbacine-based
4
himbacine-based thrombin
4
receptor antagonist
4
antagonist sch
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!